Boston Scientific (NYSE:BSX) Updates FY 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 3.430-3.490 for the period, compared to the consensus estimate of 3.460. The company issued revenue guidance of $22.2 billion-$22.4 billion, compared to the consensus revenue estimate of $22.4 billion. Boston Scientific also updated its Q1 2026 guidance to 0.780-0.800 EPS.

Boston Scientific Price Performance

BSX traded down $12.93 during trading on Wednesday, reaching $78.69. 37,947,533 shares of the company were exchanged, compared to its average volume of 13,795,622. Boston Scientific has a 12-month low of $75.00 and a 12-month high of $109.50. The company’s 50-day moving average is $94.89 and its two-hundred day moving average is $99.29. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The company has a market cap of $116.65 billion, a price-to-earnings ratio of 41.95, a P/E/G ratio of 1.63 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company’s revenue was up 15.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Research analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. National Bankshares set a $115.00 target price on Boston Scientific in a research note on Monday. Evercore ISI set a $112.00 price objective on shares of Boston Scientific in a research report on Monday, January 5th. TD Cowen reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Monday. Oppenheimer cut their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. Finally, Truist Financial lowered their price objective on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $123.26.

Insiders Place Their Bets

In other news, Director Ellen M. Zane sold 12,891 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 191,105 shares of company stock valued at $18,067,697 over the last three months. Insiders own 0.50% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat: BSX posted $0.80 EPS vs. $0.78 consensus and reported 15.9% year-over-year net sales growth — confirms underlying demand and operational momentum. Zacks: Boston Scientific Beats Q4
• Positive Sentiment: Revenue detail: net sales ~$5.29B with ~12.7% organic growth — supports medium-term revenue base and validates product momentum across several franchises. PR Newswire: Q4 Results
• Neutral Sentiment: Analyst backdrop: many firms still rate BSX a Buy with mid- to high‑teens upside targets — consensus remains constructive despite near-term headwinds. MarketBeat: Analyst Consensus
• Negative Sentiment: Soft 2026 guidance: management issued modest revenue growth and profit guidance that trailed Street expectations, which was the primary driver of the early selloff. WSJ: Profit, Sales Rise but Issues Soft Guidance
• Negative Sentiment: Electrophysiology weakness: management called out light EP sales (one of its key growth drivers), raising near-term execution concerns. Blockonomi: Why Shares Dropped
• Negative Sentiment: Market positioning and sentiment: unusually large put-option buying (≈23,490 puts, ~52% above average) indicates elevated bearish hedging/speculation adding downward pressure.
• Negative Sentiment: Insider sale: CEO Michael Mahoney sold ~160,901 shares (~$15M) last week; such a large disclosed sale can amplify negative sentiment even if preplanned. SEC Filing: Insider Sale

Institutional Trading of Boston Scientific

Several large investors have recently added to or reduced their stakes in the stock. Northern Trust Corp boosted its stake in Boston Scientific by 0.9% in the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock worth $1,406,129,000 after purchasing an additional 128,188 shares in the last quarter. Amundi raised its holdings in Boston Scientific by 17.5% in the 3rd quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock worth $1,158,619,000 after acquiring an additional 1,781,830 shares during the last quarter. Marshall Wace LLP lifted its position in Boston Scientific by 30.7% in the 3rd quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock valued at $956,680,000 after acquiring an additional 2,301,383 shares in the last quarter. Lazard Asset Management LLC boosted its stake in Boston Scientific by 1.3% during the 3rd quarter. Lazard Asset Management LLC now owns 6,719,769 shares of the medical equipment provider’s stock valued at $656,051,000 after purchasing an additional 87,009 shares during the last quarter. Finally, Man Group plc increased its holdings in shares of Boston Scientific by 79.8% in the 3rd quarter. Man Group plc now owns 3,843,937 shares of the medical equipment provider’s stock worth $375,284,000 after purchasing an additional 1,706,494 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.